David Altshuler, Vertex CSO

Mod­er­na picks up a $75M cash wind­fall as long­time col­lab­o­ra­tor Ver­tex signs up for a gene edit­ing as­sault on cys­tic fi­bro­sis

Af­ter nail­ing down the top drug fran­chise in cys­tic fi­bro­sis, Ver­tex $VRTX is turn­ing to the mR­NA afi­ciona­dos at Mod­er­na $MR­NA to use gene edit­ing tech for a gen­er­a­tion 2.0 at­tempt to mas­ter the dis­ease. This is their 3rd pact to­geth­er in 4 years as they joint­ly set their sights on the pa­tients who are tough­est to treat.

Re­searchers at Mod­er­na and Ver­tex will now work to­geth­er to de­vel­op lipid nanopar­ti­cles and mR­NA to de­liv­er gene edit­ing tools to cells in the lung to spur pro­duc­tion of func­tion­al cys­tic fi­bro­sis trans­mem­brane con­duc­tance reg­u­la­tor (CFTR) pro­tein.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.